A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.
about
Rectal pre-exposure prophylaxis (PrEP)Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate StudiesMicrobicides and their potential as a catalyst for multipurpose sexual and reproductive health technologiesA Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex VivoExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesHistorical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.A MIV-150/zinc acetate gel inhibits SHIV-RT infection in macaque vaginal explantsShort communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicidesA potent combination microbicide that targets SHIV-RT, HSV-2 and HPVAlternative divalent cations (Zn²⁺, Co²⁺, and Mn²⁺) are not mutagenic at conditions optimal for HIV-1 reverse transcriptase activity.MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancyIn search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?Developing multipurpose reproductive health technologies: an integrated strategy.A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical MucosaFirst-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.Persistent babesiosis in a Rhesus macaque (Macaca mulatta) infected with a simian-human immunodeficiency virus.The development of rectal microbicides for HIV prevention.An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy.MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1.An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.
P2860
Q26829713-94222347-35B6-49ED-B988-C9EAE7B2DBC4Q27021082-684C3250-1DF1-47C3-BD35-B5EF7C86CB32Q27026257-E8850BA3-FF51-472A-832D-381578B07AA0Q27334384-6BB24314-D90A-48EF-A903-10986176F19DQ28540200-B544CE05-7535-425D-97A1-C53F65FB14B9Q33821090-99D7DCEB-7B22-4900-AF37-E9E1A30A29E7Q33978803-11C42F52-6060-45C5-B47F-9E2571329ADFQ34258224-F4B89608-A56B-4E9A-90A5-2B27E08E391CQ34399737-436307B4-5C3D-497B-A044-48132D0C8205Q35150470-A6E42522-ADA9-42F7-B86E-900F77CA1347Q35620768-A7A90B1D-7F82-4C06-83D0-8434C964FA44Q35746218-950927E3-8D07-4C0F-A48C-0C0458A6EFAFQ36281109-592078E7-AA60-4148-AB0E-C6BCFDFA2F1EQ36381485-BA816961-E395-4438-8AA9-CDE95442D8EFQ36630547-54D880A5-512E-42CA-B335-6973C13C2815Q36692217-0D980F01-CA3F-4B53-9383-B65AC7E391E3Q37036620-95AC1A4A-480A-4BE5-B21C-957E3011C0C0Q37203838-3878F718-153F-4AF9-939D-497EE849799FQ37520083-280BEC29-F81F-474D-819F-9AE2566B94DDQ37544128-52BD104B-966F-4E36-91A2-B909FD21920DQ37706997-B2BF014E-00B5-4FA5-884F-141E3AC7B6D4Q38165222-B7D9BC36-33C5-4238-89AD-8139A09EAB13Q38689686-EDB129D6-AA02-4F73-99E6-11A8CFFB2C18Q39463175-FCF45AF4-E888-4701-8EF1-5C1119B39C71Q40081674-E93B753E-3330-49AB-AE14-8799A9FFD726Q40165275-F7B7654F-BC6F-401F-9E0E-D44E496116BEQ41033215-4DE2E19C-C4B0-4F60-A3B5-FAE23B761971Q42213704-5FD0BC27-5EA1-464B-88E4-9E9C97AA264FQ42232018-203E9CA9-A822-4FDE-92FF-5DF08D4AA5EC
P2860
A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@ast
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@en
type
label
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@ast
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@en
altLabel
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use
@en
prefLabel
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@ast
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@en
P2093
P2860
P921
P356
P1476
A single dose of a MIV-150/Zin ...... rectally 8-24 h after gel use.
@en
P2093
Agegnehu Gettie
Ciby J Abraham
James Blanchard
Jeffrey D Lifson
Jessica Kenney
José A Fernández-Romero
Melissa Robbiani
Meropi Aravantinou
Michael Piatak
Nina Derby
P2860
P304
P356
10.1089/AID.2012.0087
P407
P577
2012-07-30T00:00:00Z